CECAD Microsite

Publications

Heilmann, T., Vondung, F., Borzikowsky, C., Szymczak, S., Krüger, S., Alkatout, I., Wenners, A., Bauer, M., Klapper, W., Röcken, C., Maass, N., von Karstedt, S., Schem, C., Trauzold, A., 2019. Heterogeneous intracellular TRAIL-receptor distribution predicts poor outcome in breast cancer patients. Journal of Molecular Medicine 97, 1155–1167.

 

Lim, J.K.M., Delaidelli, A., Minaker, S.W., Zhang, H.-F., Colovic, M., Yang, H., Negri, G.L., von Karstedt, S., Lockwood, W.W., Schaffer, P., u. a. (2019). Cystine/glutamate antiporter xCT (SLC7A11) facilitates oncogenic RAS transformation by preserving intracellular redox balance. Proceedings of the National Academy of Sciences 201821323.

 

Kretz, A.-L., Trauzold, A., Hillenbrand, A., Knippschild, U., Henne-Bruns, D., von Karstedt, S., und Lemke, J. (2019). TRAILblazing Strategies for Cancer Treatment. Cancers 11, 456.

 

García-Reyes, B., Kretz, A.-L., Ruff, J.-P., von Karstedt, S., Hillenbrand, A., Knippschild, U., Henne-Bruns, D., und Lemke, J. (2018). The Emerging Role of Cyclin-Dependent Kinases (CDKs) in Pancreatic Ductal Adenocarcinoma. International Journal of Molecular Sciences 19, 3219.

 

Anna-Laura Kretz, Silvia von Karstedt, Andreas Hillenbrand, Doris Henne-Bruns, Uwe Knippschild, Anna Trauzold, Johannes Lemke. Should We Keep Walking along the Trail for Pancreatic Cancer Treatment? Revisiting TNF-Related Apoptosis-Inducing Ligand for Anticancer Therapy. Cancers (2018), 10(3), 77; doi:10.3390/cancers10030077

 

von Karstedt, S; NDRG2 programs Tumor-Associated Macrophages for Tumor support. Cell Death and Disease (2018) vol. 9 (3) p. 294.

 

Krishna K. Kolluri, Constantine Alifrangis, Neelam Kumar, Stacey Price, Magali Michaut, Steven Williams, Syd Barthorpe, Yuki Ishii, Howard Lightfoot, Sara Busacca, Annabel Sharkey, Zhenqiang Yuan, Elizabeth K. Sage, Sabarinath Vallath, John Le Quesne, David A. Tice, Doraid Alrifai, Silvia von Karstedt, Antonella Montinaro, Naomi Guppy, David A. Waller, Apostolos Nakas, Robert Good, Alan Holmes, Henning Walczak, Dean A. Fennell, Mathew J. Garnett, Francesco Iorio, Lodewyk F. A. Wessels, Ultan McDermott, Sam M. Janes; Loss of functional BAP1 augments sensitivity to TRAIL in cancer cells. eLife Sciences  (2018) 7, 155.

 

von Karstedt, S.*, Montinaro, A.*, and Walczak, H. (2017). Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy. Nature Reviews Cancer 2017, 352–366.   *equal contribution

 

Hartwig, T.*, Montinaro, A.*, von Karstedt, S.*, Sevko, A., Surinova, S., Chakravarthy, A., Taraborrelli, L., Draber, P., Lafont, E., Arce Vargas, F., Bahrawy, M. A., Quezada, S. A., and Walczak, H.. The TRAIL-induced cancer secretome promotes a tumor-supportive immune-microenvironment via CCR2. Molecular Cell 2017 65, 730–742.e5.* equal contribution

 

Zinngrebe, J.*, Rieser, E.*, Taraborrelli, L., Peltzer, N., Ren, H., Kovács, I., Endres, C., Draber, P., Darding, M., von Karstedt, S., Lemke, J., Dome, B., Bergmann, M., Ferguson, B. J., Walczak, H.; LUBAC deficiency perturbs TLR3 signaling to cause immunodeficiency and autoinflammation. Journal of Experimental Medicine 2016 213, 2671-2689, doi:10.1084/jem.20160041. * equal contribution.

 

Peintner, L., Novelli, F., Smirnov, A., Maurer, U., Borner, C., and von Karstedt, S. 9th Tuscany Retreat on Cancer Research: genetic profiling, resistance mechanisms and novel treatment concepts in cancer. Cell Death and Differentiation 2016 ; 23:183-184.

 

von Karstedt, S., Conti, A., Nobis, M., Montinaro, A., Hartwig, T., Lemke, J., Legler, K., Annewanter, F., Campbell, A.D., Taraborrelli, L., et al. Cancer Cell-Autonomous TRAIL-R Signaling Promotes KRAS-Driven Cancer Progression, Invasion, and Metastasis. Cancer Cell 2015; 27:561-573.

 

Tuthill MH, Montinaro A, Zinngrebe J, Prieske K, Draber P, Prieske S, T Newsom-Davis, S von Karstedt, J Graves, H Walczak; TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells. Oncogene 2015; 34(16): 2138-44.

 

Lemke J, von Karstedt S, Abd El Hay M, Conti A, Arce F, Montinaro A et al. Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1. Cell Death and Differentiation 2014; 21(3): 491-502.

 

von Karstedt S & Peltzer N. Fire raiser or fire accelerant? A meeting report on the 14th International TNF Conference 2013. Cell Death and Differentiation 2014; 21(8): 1343-4.

 

Lemke J, Scheele J, Kapapa T, von Karstedt S, Wirtz CR, Henne-Bruns D; Brain metastases in gastrointestinal cancers: is there a role for surgery? International journal of molecular sciences 2014; 15(9): 16816-30.

 

Lemke J, von Karstedt S, Zinngrebe J, Walczak H. Getting TRAIL back on track for cancer therapy. Cell Death and Differentiation 2014; 21(9): 1350-64.

 

Papenfuss K*, Prieske S*, Walczak H. TRAIL-Rezeptor-Agonisten, eine neue Klasse proapoptotischer Krebstherapeutika. English: TRAIL Receptor Agonists, a Novel Class of Pro-Apoptotic Agents in Cancer Therapy. Onkopipeline 2010; 3(1): 11-23.

 

Newsom-Davis T*, Prieske S*, Walczak H. Is TRAIL the holy grail of cancer therapy? Apoptosis : an international journal on programmed cell death. 2009 Apr;14(4):607-23.